US assessment of HPV Types in cancers: Implications for current and 9-valent HPV vaccines

Journal of the National Cancer Institute

Volumn 107, Issue 6, 2015, Pages

  Saraiya, Mona ^a   Unger, Elizabeth R ^b   Thompson, Trevor D ^a   Lynch, Charles F ^d   Hernandez, Brenda Y ^c   Lyu, Christopher W ^e   Steinau, Martin ^b   Watson, Meg ^a   Wilkinson, Edward J ^g   Hopenhayn, Claudia ⁱ   Copeland, Glenn ^h   Cozen, Wendy ^l   Peters, Edward S ^f   Huang, Youjie ^j   Saber, Maria Sibug ^e   Altekruse, Sean ^k   Goodman, Marc T ^c,m  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^g UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^h MICHIGAN DEPARTMENT OF COMMUNITY HEALTH   (United States)

ⁱ UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

^j FLORIDA DEPARTMENT OF HEALTH   (United States)

^k NATIONAL CANCER INSTITUTE   (United States)

^l BATTELLE MEMORIAL INSTITUTE   (United States)

^m CEDARS SINAI MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; VIRUS DNA; WART VIRUS VACCINE;

ADULT; AGED; ANUS CANCER; ARTICLE; CANCER IMMUNIZATION; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN TISSUE; INFECTION PREVENTION; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MIDDLE AGED; MOUTH CANCER; OROPHARYNX CANCER; PAPILLOMAVIRUS INFECTION; PENIS CANCER; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA IN SITU; VAGINA CANCER; VIRUS DETECTION; VULVA CANCER; ALPHAPAPILLOMAVIRUS; COMPLICATION; EPIDEMIOLOGY; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; LARYNGEAL NEOPLASMS; NEOPLASMS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PENILE NEOPLASMS; REGISTER; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VIROLOGY; VULVAR NEOPLASMS;

ADULT; AGED; ALPHAPAPILLOMAVIRUS; DNA, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PENILE NEOPLASMS; REGISTRIES; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VULVAR NEOPLASMS;

EID: 84930709415     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv086     Document Type: Article

References (46)

1. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342-350.
2. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl 5):F12-F23.
3. International Agency for Research on Cancer IARC. Monographs on the evaluation of carcinogenic risks to humans: biologic agents. Human papillomaviruses. Vol. 100B. Lyon, France: IARC; 2012. http://monographs.iarc.fr/ENG/Monographs/vol100B/mono100B-11.pdf
4. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens-Part B: biological agents. The Lancet Oncol. 2009; 10(4):321-322.
5. Doorbar J, Quint W, Banks L, et al. The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30(Suppl 5):F55-F70.
6. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294-4301.
7. Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer. 2008;113(10 Suppl):3036-3046.
8. Baldur-Felskov B, Dehlendorff C, Munk C, et al. Early impact of human papillomavirus vaccination on cervical neoplasia-nationwide follow-up of young Danish women. J Natl Cancer Inst. 2014;106(3):djt460 doi:10.1093/jnci/djt460.
9. Gertig DM, Brotherton JM, Budd AC, et al. Impact of a population-based HPV vaccination program on cervical abnormalities: A data linkage study. BMC Med. 2013;11:227.
10. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576-1585.
11. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364(5):401-411.
12. FUTURE I/II Study Group, Dillner J, Kjaer SK, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010;341:c3493.
13. Kreimer AR, Gonzalez P, Katki HA, et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: A nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol. 2011;12(9):862-870.
14. Herrero R, Quint W, Hildesheim A, et al. Reduced prevalence of oral humanpapillomavirus (HPV) 4 Years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One. 2013;8(7):e68329.
15. Food and Drug Administration. Highlights of prescribing information. Gardasil 9 (human papillomavirus nonvalent [types 6, 11, 16, 18, 31, 33, 45, 52, and 58]). Silver Spring, MD: US Department of Health and Human Services; Food and Drug Administration; 2014. Available at http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM426457.pdf
16. Chatterjee A. The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon. Expert Rev Vaccines. 2014;13(11):1279-1290.
17. Serrano B, Alemany L, Tous S, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer. 2012;7(1):38.
18. CDC. Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013-United States. MMWR Morb Mortal Wkly Rep. 2013;62(29):591-595.
19. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048-1056.
20. Gargano JW, Wilkinson EJ, Unger ER, et al. Prevalence of human papillomavirus types in invasive vulvar cancers and vulvar intraepithelial neoplasia 3 in the United States before vaccine introduction. J Low Genit Tract Dis. 2012;16(4):471-479.
21. Steinau M, Unger ER, Hernandez BY, et al. Human papillomavirus prevalence in invasive anal cancers in the United States before vaccine introduction. J Low Genit Tract Dis. 2013;17(4):397-403.
22. Hernandez BY, Goodman MT, Unger ER, et al. Human papillomavirus genotype prevalence in invasive penile cancers from a registry-based United States population. Front Oncol. 2014;4:9.
23. Hopenhayn C, Christian A, Christian WJ, et al. Prevalence of human papillomavirus types in invasive cervical cancers from 7 US cancer registries before vaccine introduction. J Low Genit Tract Dis. 2014;18(2):182-189
24. Sinno AK, Saraiya M, Thompson TD, et al. Human papillomavirus genotype prevalence in invasive vaginal cancer from a registry-based population. Obstet Gynecol. 2014;123(4):817-821.
25. Onyekwuluje JM, Steinau M, Swan DC, et al. A real-time PCR assay for HPV52 detection and viral load quantification. Clin Lab. 2012;58(1-2):61-66.
26. Insinga RP, Liaw KL, Johnson LG, et al. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev. 2008;17(7):1611-1622.
27. Wentzensen N, Schiffman M, Dunn T, et al. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer. 2009;125(9):2151-2158.
28. Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013;105(3):175-201.
29. CDC. Human papillomavirus-associated cancers-United States, 2004-2008. MMWR Morb Mortal Wkly Rep. 2012;61:258-261.
30. Alemany L, Saunier M, Alvarado-Cabrero I, et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer. 2015;136(1):98-107.
31. Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128(4):927-935.
32. Wheeler CM, Hunt WC, Joste NE, et al. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst. 2009;101(7):475-487.
33. Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131(10):2349-2359.
34. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-19.
35. Liebrich C, Brummer O, Von Wasielewski R, et al. Primary cervical cancer truly negative for high-risk human papillomavirus is a rare but distinct entity that can affect virgins and young adolescents. Eur J Gynaecol Oncol. 2009;30(1):45-48.
36. Hariri S, Unger ER, Powell SE, et al. Human papillomavirus genotypes in high-grade cervical lesions in the United States. J Infect Dis. 2012;206(12):1878-1886.
37. Moscicki AB, Schiffman M, Burchell A, et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine. 2012;30(Suppl 5):F24-F33.
38. de Sanjose S, Wheeler CM, Quint WG, et al. Age-specific occurrence of HPV16-and HPV18-related cervical cancer. Cancer Epidemiol Biomarkers Prev. 2013;22(7):1313-1318
39. Backes DM, Kurman RJ, Pimenta JM, et al. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control. 2009;20(4):449-457.
40. Gillison ML, Alemany L, Snijders PJ, et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine. 2012;30(Suppl 5):F34-F54.
41. Castellsague X AL, Holzinger D, de Sanjosé D, et al. Estimation of the HPV etiological fraction in over 4,000 head and neck cancers worldwide. In: PH.PD03.01. 29th International Papillomavirus Conference Seattle, WA; August, 2014.
42. Combes JD, Franceschi S. Role of human papillomavirus in non-oropharyngeal head and neck cancers. Oral Oncol. 2014;50(5):370-379.
43. Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA. 2012;307(7):693-703.
44. D'Souza G, Cullen K, Bowie J, et al. Differences in oral sexual behaviors by gender, age, and race explain observed differences in prevalence of oral human papillomavirus infection. PLoS One. 2014;9(1):e86023.
45. Settle K, Posner MR, Schumaker LM, et al. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila). 2009;2(9):776-781.
46. Saraiya M, Goodman MT, Datta SD, et al. Cancer registries and monitoring the impact of prophylactic human papillomavirus vaccines: The potential role. Cancer. 2008;113(10 Suppl):3047-3057.